

**To Financial Editors:
【For Immediate Release】**



**TUL Obtained Products Approval for Recombinant Human Insulin Product
Full Sights on the Multi-billion Market**

【13 December 2009 - Hong Kong】- The United Laboratories International Holdings Limited (“TUL” or the “Group”; Stock code: 3933), one of the leading pharmaceutical companies in the PRC, is pleased to announce that the Group has obtained official production approval for a recombinant human insulin product. The brand name of product is “USLIN”.

USLIN is a kind of recombinant human insulin product that is mainly used for clinical treatment of type 1 and type 2 diabetes. Such patients usually need lifelong medication. Not only can this product maintain the body's normal blood glucose levels, but also it can affect the metabolism of fat and protein and to maintain a stable intracellular environment. As a result, the product can reduce the incidence of complications of diabetes and improve the living quality of diabetes patients. Currently, China's diabetes patients are more than 100 million. The demand for recombinant human insulin products in China is about 4 billion RMB per year. The market expects the demand continues to grow by 20% to 30% each year in the coming future.

In 2006-2008, TUL invited the State Key Laboratories of Virology to carry out controlled clinical trials between USLIN and some major imported insulin series. Results show that the equivalent treatment effectiveness of the new product is equivalent to that of the imported insulin series. This laid the foundation for The Group to seize the market.

Mr. Choy Kam Lok, Chairman of TUL said, “The Group has been committed to enter the fast-growing Chinese insulin market which has strong demand for good medicines. It is a piece of exciting news about the approval of USLIN. In terms of price and quality point of view, the product is highly competitive in the market. This definitely gives a new impetus to the Group. In the future, the Group will continue to increase investment in research and development in order to produce more diverse and competitive products and thus to enhance shareholders’ returns.”

- End -

About The United Laboratories International Holdings Limited

Listed on the Stock Exchange of Hong Kong in June 2007, TUL is one of the leading pharmaceutical companies in China, principally engaged in the manufacturing and selling of medicines, and the bulk and intermediate products used to produce finished goods. As of 30 June 2009, the Group has a total of 168 products qualified to produce in the PRC and/Hong Kong based on the Drug Registration Approvals in the PRC and Certificates of Drug or Product Registration in Hong Kong. 76 were in

production, and 34 were listed in Insurance Catalogue. 12 finished products are in the list of National Basic Drugs Catalogue. For more information about TUL, please visit the company's website at www.tul.com.hk.

Issued by Creativeline Communications for and on behalf of The United Laboratories International Holdings Limited. For further information, please contact:

Creativeline Communications

Mr. Wayne Chau / Ms. Sylvia Lau

Tel: (852) 2730 6212 / 6390 9406

Fax: (852) 2736 0745

Email: wayne@creativeline.com.hk / sylvia@creativeline.com.hk